Kestra Medical initiated with a Neutral at Goldman Sachs

Goldman Sachs initiated coverage of Kestra Medical (KMTS) with a Neutral rating and $24 price target The firm says the company’s sales growth profile in combination with a continued gross margin inflection “provides a compelling opportunity.” However, the shares at current levels appropriately capture Kestra Medical’s forward outlook, the analyst tells investors in a research note.